exRNAdisease

General Information

Database ID:

exR0075990

RNA Name:

LCP1

RNA Type:

mRNA

Chromosome:

chr13

Starnd:

Coordinate:

Start Site(bp):

46125920

End Site(bp):

46211871

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCD4	chr14	74285269	74303055	-
AC004922.1	chr7	99325879	99394653	+
AC008982.1	chr19	38817471	38840178	-
AC012254.2	chr18	47108188	47176345	-
AC023055.1	chr12	55757275	55827546	-
ACAP2	chr3	195274745	195443044	-
ACBD5	chr10	27195214	27242130	-
ACP1	chr2	264140	278283	+
ACSS1	chr20	25006230	25058980	-
ACTB	chr7	5527148	5563784	-
ACTBL2	chr5	57480018	57482811	-
ACTG1	chr17	81509971	81523847	-
ACTR3C	chr7	150243916	150323725	-
ADAR	chr1	154582057	154628013	-
ADSL	chr22	40346500	40390463	+
AFG3L2	chr18	12328944	12377227	-
AFTPH	chr2	64524305	64593005	+
AGPAT4	chr6	161129967	161274061	-
AHSA1	chr14	77457870	77469472	+
AKR1A1	chr1	45550543	45570049	+
AL021546.1	chr12	120438198	120460006	+
AL022238.4	chr22	40346529	40410054	+
AL109827.1	chr20	35632340	35674544	-
AL139300.1	chr14	103562962	103685924	+
ALAS1	chr3	52198086	52214327	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-155-5p	chr21	25573983	25574006	+

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC006064.5	chr12	6510275	6510522	+
AC026202.2	chr3	5156905	5187329	-
AC026202.3	chr3	5187172	5188298	-
AC055860.1	chr11	18000542	18022931	-
AC079781.5	chr7	97851688	97972985	-
AC135048.1	chr16	30948386	30956511	+
AC245014.3	chr1	145281116	145281462	+
AL022311.1	chr22	37876148	37895563	+
AL137058.2	chr13	52600042	52642542	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference